Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.46 |
| ▸ | ITGAV | P06756 | 10/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 8/20 | 0.45 |
| ▸ | MC5R | P33032 | 8/20 | 0.45 |
| ▸ | MC3R | P41968 | 8/20 | 0.45 |
| ▸ | MC1R | Q01726 | 8/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365734 | 1.00 | ITGB3 (0.46) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL8366215 | 0.95 | ITGB3 (0.46) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL7746015 | 0.92 | MC4R (0.44) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL7743862 | 0.92 | MC4R (0.44) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL14585806 | 0.92 | MC4R (0.44) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL7746130 | 0.92 | MC4R (0.44) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL8363713 | 0.91 | ITGB3 (0.43) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL8365683 | 0.90 | KDM4A (0.44) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL7744204 | 0.89 | ITGB3 (0.43) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL8365680 | 0.88 | ITGB3 (0.41) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |